For research use only. Not for therapeutic Use.
Benralizumab（Cat No.:I017510） is a monoclonal antibody used for the treatment of severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis. It specifically targets and binds to the interleukin-5 receptor (IL-5R), inhibiting the binding of IL-5 and subsequently reducing eosinophilic inflammation. Benralizumab is administered by subcutaneous injection and has demonstrated efficacy in reducing exacerbations and improving lung function in patients with eosinophilic asthma.
| Catalog Number | I017510 |
| CAS Number | 1044511-01-4 |
| Purity | ≥95% |
| Storage | Store at 4°C, do not freeze |
| Reference | [1]. Menzies-Gow A, et al. Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Res. 2019 Sep 25;5(3). pii: 00009-2019. |
